Published: Mar 15, 2021
Indiana-based radiopharmaceutical Contract Development and Manufacturing Organization expands nuclear pharmacy capabilities with second location
SpectronRx, a leading radiopharmaceutical contract development and manufacturing organization (CDMO), announced today that the U.S. Nuclear Regulatory Commission (NRC) has issued a Materials License for its new Indianapolis, IN headquarters. The license also expands SpectronRx’s roster of authorized nuclear pharmacists and authorized users. The news comes as SpectronRx continues to scale its early-stage development and commercialization services for leading pharmaceutical companies working to develop and deploy radiopharmaceutical compounds for the treatment and detection of certain cancers and other diseases.
“Securing Nuclear Regulatory Commission materials licensing for our new headquarters and additional staff is a significant milestone for the growth of SpectronRx,” said John Zehner,